EUVIMEDEUVIMED entdecken
Crossref

Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes

Harshitha Mogallapalli, Fauzia Osman, Sandesh Parajuli, Neetika Garg, Fahad Aziz, Arjang Djamali, Brad C Astor, Maha A Mohamed

Transplantation Proceedings · 2025

DOI: 10.1016/j.transproceed.2025.03.023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Harshitha Mogallapalli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Hauptthemen laut MEDLINE: Abatacept, Kidney Transplantation, Heart Failure, Patient Readmission. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Herman and Gwendolyn Shapiro Foundation, University of Wisconsin-Madison School of Medicine and Public Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcineurin inhibitors (CNIs) are deleterious to cardiovascular risk in kidney transplant recipients (KTRs). Data on the impact of belatacept on KTRs with congestive heart failure (CHF) are scarce. We hypothesized that conversion to belatacept will have better patient and graft survival and a lower rate of readmissions within 30 days after discharge compared with long-term CNI use. We analyzed data from KTRs admitted to CHF between 2014 and 2019. A total of 28 recipients converted to belatacept and were matched with 339 who continued on CNIs. There was no significant difference in patient demographics, or primary disease between the two groups. The adjusted hazard ratio associated with conversion was (0.87 [95% CI, 0.35-2.11] for death, (0.91, [95% CI, 0.39-2.13] for graft failure and (adjusted hazard ratio, 1.91, [95% confidence interval (CI), 0.90-4.06]) for 30-day postdischarge readmission between the two groups. Patients converted to belatacept were at a higher risk of rejection (adjusted hazard ratio, 13.8; 95% CI, 7.48-25.3). Patient and graft survival and 30-day readmission after CHF hospital discharge did not differ significantly between belatacept conversion and CNI continuation. The incidence of rejection was higher in the belatacept conversion group, suggesting a need for closer follow-up of patients on belatacept therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptKidney TransplantationHeart FailurePatient ReadmissionImmunosuppressive AgentsHumansMaleFemaleMiddle AgedGraft SurvivalGraft RejectionRetrospective StudiesCalcineurin InhibitorsTreatment OutcomeAgedAdult

Substanzen

AbataceptImmunosuppressive AgentsCalcineurin Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
  • Department of Medicine, Main Medical Center, Portland, Main.
  • Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; Department of Population Health Sciences, University of Wisconsin, Madison, Wisconsin.
  • Department of Medicine, Stanford University School of Medicine, Stanford, California. Electronic address: mmohame2@stanford.edu.

Förderung

  • Herman and Gwendolyn Shapiro Foundation
  • University of Wisconsin-Madison School of Medicine and Public Health

Zitieren

APA

Mogallapalli, H., Osman, F., Parajuli, S., Garg, N., Aziz, F., Djamali, A., Astor, B. C., & Mohamed, M. A. (2025). Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.03.023

Vancouver

Mogallapalli H, Osman F, Parajuli S, Garg N, Aziz F, Djamali A, et al. Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.03.023

BibTeX
@article{Mogallapalli2025,
  author = {Mogallapalli, Harshitha and Osman, Fauzia and Parajuli, Sandesh and Garg, Neetika and Aziz, Fahad and Djamali, Arjang and Astor, Brad C and Mohamed, Maha A},
  title = {Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes},
  journal = {Transplantation Proceedings},
  year = {2025},
  doi = {10.1016/j.transproceed.2025.03.023}
}
Kostenlos starten →